Monopar Therapeutics Advances Rolling NDA Submission in Wilson Disease

Monopar Therapeutics' rolling NDA submission for ALXN1840, initiated with FDA authorization on July 22, 2026, is now weeks from completion, placing Wilson disease regulatory teams on notice that a first-in-class copper chelation candidate is moving through the agency's review pipeline in real time. For regulatory affairs leads managing orphan indication strategy, the submission sequence offers a working reference point on how rolling review compresses the NDA timeline without sacrificing module integrity.

The clinical rationale underpinning the application gained additional weight at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026, where Monopar presented baseline data from the Phase 3 FoCus study, described as the largest randomized controlled trial conducted in Wilson disease. Among treatment-experienced patients enrolled, only 47% were within guideline-recommended copper target range, and 31% of those on standard-of-care therapy for more than 12 months showed 24-hour urinary copper excretion above that threshold. Cirrhosis was present in 39% of treatment-experienced patients; 73% of evaluable patients carried at least two of the tracked disease manifestations.

A separate AASLD poster reported neutral molybdenum balance and no molybdenum toxicity across six years of ALXN1840 exposure, with serum uric acid remaining within normal limits throughout. The findings align with the drug's albumin tripartite complex (ATC) mechanism and are directly relevant to the long-term safety sections of the NDA package under rolling review.

On the operational side, Monopar appointed Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs in August 2026, signaling pre-approval build-out of the medical affairs function ahead of a potential FDA decision. Kent brings more than 20 years of experience across rare disease, hepatology, and regulatory strategy, a profile consistent with the cross-functional demands of an orphan drug launch.

Financially, Monopar reported a Q3 2026 net loss of $6.2 million, up from $3.4 million in Q3 2025, with R&D expenses rising to $4.4 million from $2.6 million year-over-year. The increase was driven primarily by contractor and consulting costs tied to the NDA build, partially offset by a reduction in ALXN1840 manufacturing activity, a pattern consistent with a program transitioning from late-stage production to submission execution. Cash and investments stood at $129.4 million as of September 30, 2026, with the company projecting runway through at least March 31, 2028.

Completion of the rolling NDA submission within the stated several-week window will determine when FDA's review clock formally starts, the next measurable checkpoint for regulatory teams tracking this orphan indication.

Source: Monopar Therapeutics Inc. via GlobeNewswire, November 12, 2026.